Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 4/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albizziine SCHEMBL9361011 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL439790 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL690347 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL1006298 | 1.00 | GFPT1 (0.48) | GFPT1ALOX15BLMPMP22KMT2A | |
| Albizziine SCHEMBL29791573 | 0.98 | GFPT1 (0.47) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL31524073 | 0.82 | CYP2D6 (0.50) | GFPT1PTGS1SLC7A11GGT1SLC7A5 | |
| SCHEMBL1527344 | 0.81 | GFPT1 (0.46) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL574087 | 0.81 | GFPT1 (0.46) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL393844 | 0.81 | GFPT1 (0.46) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL1512859 | 0.81 | SLC7A5 (0.43) | ALOX15BLMPMP22KMT2APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081955-B1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | claimed |
| US-20190202883-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3467106-A1 | PEPTIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-10087229-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-3210998-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| EP-2314609-B1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20160052988-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9200051-B2 | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2081955-B1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140357552-A1 | PEPTIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-04 | — | — | US | disclosed |
| US-7786083-B2 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-31 | — | — | US | disclosed |
| WO-2010076896-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-08 | — | — | WO | disclosed |
| US-20090215700-A1 | Metastin derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2081955-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090105152-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20090099334-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1963362-A1 | METASTIN DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008050897-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007072997-A1 | METASTIN DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215700-A1 | Metastin derivatives and use thereof | SHBG, GNRHR, INHA | GFPT1 1436/4885ALOX15 4766/4885BLM 2917/4885 |
| US-20160052988-A1 | PEPTIDE COMPOUND | GIPR, GLP1R, VIP | GFPT1 1820/4885ALOX15 2806/4885BLM 4288/4885 |
| US-20090099334-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | GFPT1 1264/4885ALOX15 4736/4885BLM 3240/4885 |
| US-20190202883-A1 | PEPTIDE COMPOUND | IAPP, VIP, GLP1R | GFPT1 1740/4885ALOX15 3011/4885BLM 3341/4885 |
| US-20140357552-A1 | PEPTIDE COMPOUND | GLP1R, GIPR, VIP | GFPT1 2322/4885ALOX15 3764/4885BLM 4570/4885 |
| US-20090093615-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | GFPT1 1264/4885ALOX15 4736/4885BLM 3240/4885 |
| US-20090105152-A1 | METASTIN DERIVATIVES AND USE THEREOF | SHBG, GNRHR, INHA | GFPT1 1264/4885ALOX15 4736/4885BLM 3240/4885 |
| US-10087229-B2 | Peptide compound | GLP1R, GIPR, VIP | GFPT1 2433/4885ALOX15 3671/4885BLM 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.